Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03151109 · ClinicalTrials.gov registry record
Glenoid Bone Grafting for RTSA: Clinical & Radiographic Outcomes
A clinical trial, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- 67
- Enrollment target
NCT03151109: Completed study, sponsored by Washington University School of Medicine.
NCT03151109 is a clinical trial that has completed, run by Washington University School of Medicine. The registered enrollment target is 67 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03151109 has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- 67 participants
- Enrollment target
Study Summary
This study will look at patient radiographic and functional outcomes who have or will undergo a reverse, extended peg, shoulder arthroplasty (replacement) that requires the use of glenoid bone grafting.
Primary Outcome
Evaluate Bone Graft Incorporation - review images to determine signs of humeral or glenoid radiolucency, radiographic loosening, fracture, notching, and graft incorporation versus resorption on CT and/or XRay images.
Interventions
- DIAGNOSTIC_TEST CT Scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2016-09-01 |
| Est. Completion | 2021-06 |
What the finished NCT03151109 record still lists
NCT03151109 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 67 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which CT Scan is the first listed.
NCT03151109 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03151109 about?
NCT03151109 is a clinical study titled "Glenoid Bone Grafting for RTSA: Clinical & Radiographic Outcomes". This study will look at patient radiographic and functional outcomes who have or will undergo a reverse, extended peg, shoulder arthroplasty (replacement) that requires the use of glenoid bone grafting.
What is the current status of trial NCT03151109?
This trial is currently completed. The enrollment target is 67 participants. The study started on 2016-09-01. Estimated completion is 2021-06.
What interventions are being tested in trial NCT03151109?
The interventions under investigation include: CT Scan (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03151109?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI